除了PARP抑制之外的卵巢癌治疗:当前和未来的选择
Vikas Garg1, Amit M Oza2,3,4
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Drugs
|September 22, 2023
概括
卵巢癌仍然是妇科死亡的主要原因. 本综述探讨了对多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 的耐药性机制以及克服治疗失败的策略.
科学领域:
- 妇科瘤学 妇科瘤学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢癌是妇科癌症死亡率的主要原因.
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 改善了治疗,但耐药性仍然是一个挑战.
- 一半的卵巢癌患者仍然在5年内死于这种疾病.
研究的目的:
- 审查卵巢癌中对PARPi和化疗耐药性的机制.
- 讨论克服治疗失败和改善患者结果的策略.
- 探索用于管理抗性卵巢癌的新疗法.
主要方法:
- 关于卵巢癌治疗耐药性的当前文献的综述.
- 分析PARPi电阻的主要机制.
- 探索克服抗性的治疗策略.
主要成果:
- 关键的抵抗机制包括恢复同源重组修复,改变的PARP功能和药物排泄.
- 克服抵抗的策略包括使用PARPi重新挑战,准抵抗路径或绕过它们.
- 组合疗法 (PARPi与DNA损伤反应剂,抗血管生成药物或免疫检查点抑制剂) 是有前途的.
结论:
- 了解PARPi耐药性对于改善卵巢癌治疗至关重要.
- 针对抗性机制和探索新的治疗组合对于更好的结果至关重要.
- 未来的研究应该专注于克服卵巢癌治疗失败.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:27Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
01:30Cancer Vaccines
396
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
396
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K